Stephan et al. harbored ovarian-cancer-specific T cells (NKG2D-targeted CAR-T cells) and T cell stimulants into bioengineered polymer matrices and used them for tumor treatment by situating implants near the tumor. This evidence concerns the gene KLRK1 and neoplasm.